Who Owns Neurocrine Biosciences Stock?
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 104.80%
- Institutions (% of float)
- 105.94%
- Held by insiders
- 1.08%
- Institutional holders
- 1,138
- Institutions 98.9%
- Insiders 1.1%
- Public and other 0.0%
Who owns Neurocrine Biosciences stock?
Institutional investors own about 104.8% of Neurocrine Biosciences's shares, spread across 1,138 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.08% of NBIX.
The largest institutional holders are Blackrock Inc. (14.68%), Dodge & Cox Inc. (5.44%) and JPMORGAN CHASE & CO (5.23%). Together, the top 10 institutions control 49.5% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their NBIX positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of NBIX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 14.86M | 14.68% | +8.3% |
| Dodge & Cox Inc. | 5.50M | 5.44% | -1.4% |
| JPMORGAN CHASE & CO | 5.29M | 5.23% | -17.3% |
| Vanguard Portfolio Management LLC | 5.06M | 5.00% | +1.7% |
| State Street Corporation | 4.81M | 4.75% | +9.6% |
| Vanguard Capital Management LLC | 4.58M | 4.53% | +0.8% |
| AQR Capital Management, LLC | 3.06M | 3.03% | -19.8% |
| Vestal Point Capital, LP | 2.50M | 2.47% | +33.0% |
| Renaissance Technologies, LLC | 2.30M | 2.27% | -1.5% |
| Geode Capital Management, LLC | 2.13M | 2.10% | -0.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of NBIX
| Fund | Shares | % Held |
|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.96M | 3.92% |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.62M | 3.58% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19M | 3.15% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.30M | 2.28% |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.36M | 1.34% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.33M | 1.31% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15M | 1.14% |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.12M | 1.10% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 952.49K | 0.94% |
| iShares Trust-iShares Biotechnology ETF | 784.02K | 0.77% |
Frequently asked questions
Who is the largest shareholder of Neurocrine Biosciences?
Blackrock Inc. is the largest institutional shareholder of NBIX, owning 14.68% of shares outstanding (14.86M shares) as of its latest 13F filing.
What percentage of Neurocrine Biosciences is owned by institutions?
Institutions own about 104.8% of NBIX shares and 105.9% of the public float.
How much of Neurocrine Biosciences do insiders own?
Insiders, such as officers and directors, own about 1.08% of NBIX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.